Alzheimer’s disease (AD) is marked by amyloid-beta (Aβ) plaques and tau tangles. Current Aβ-targeting immunotherapies are limited by toxicities. Furthermore, recent studies suggest that aging microglia struggle with Aβ clearance and inflammation. In this study, we developed an Axl-based chimeric antigen receptor (CAR) for better Aβ clearance and reduced inflammation. By transducing CAR genes into induced microglia, the study confirmed superior Aβ uptake and lower inflammatory cytokine secretion. TAM-CAR, unlike conventional CPRs, offers effective antigen phagocytosis without inflammation, showing promise for AD therapy by replacing dysfunctional microglia and enhancing Aβ clearance.